The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade ...

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, ...

Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

A new overview details emerging medical and wellness trends, underscoring advances that broaden treatment access and inform preventive care. GLP-1 drugs such as Ozempic and Wegovy extend to heart, ...

Analysts say TrumpRx, the Trump administration's consumer drug-pricing site, might not deliver lower drug prices for most Americans.

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock ...